Version 1
: Received: 4 July 2021 / Approved: 6 July 2021 / Online: 6 July 2021 (12:40:31 CEST)
How to cite:
Liu, H.; Zhan, H.; Zhang, Y.; He, G.; Wang, H.; Zhang, Q.; Zheng, L. Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status After Neoadjuvant Chemotherapy in Chinese Women With Breast Cancer. Preprints2021, 2021070147
Liu, H.; Zhan, H.; Zhang, Y.; He, G.; Wang, H.; Zhang, Q.; Zheng, L. Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status After Neoadjuvant Chemotherapy in Chinese Women With Breast Cancer. Preprints 2021, 2021070147
Liu, H.; Zhan, H.; Zhang, Y.; He, G.; Wang, H.; Zhang, Q.; Zheng, L. Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status After Neoadjuvant Chemotherapy in Chinese Women With Breast Cancer. Preprints2021, 2021070147
APA Style
Liu, H., Zhan, H., Zhang, Y., He, G., Wang, H., Zhang, Q., & Zheng, L. (2021). Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status After Neoadjuvant Chemotherapy in Chinese Women With Breast Cancer. Preprints. https://doi.org/
Chicago/Turabian Style
Liu, H., Qiaoxia Zhang and Lili Zheng. 2021 "Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status After Neoadjuvant Chemotherapy in Chinese Women With Breast Cancer" Preprints. https://doi.org/
Abstract
Background: The present retrospective study was designed to evaluate the relative diagnostic utility of breast-specific gamma imaging (BSGI) and breast magnetic resonance imaging (MRI) as means of evaluating female breast cancer patients in China. Methods: A total of 229 malignant breast cancer patients underwent ultrasound, mammography, BSGI, and MRI between January 2015 and December 2018 for initial tumor staging. Of these patients, 73 were subsequently treated via definitive breast surgery following neoadjuvant chemotherapy (NAC), of whom 17 exhibited a complete pathologic response (pCR) to NAC. Results: BSGI and MRI were associated with respective 76.8% and 69.6% sensitivity values as a means of detecting residual tumors following NAC, while both of these approaches exhibited comparable specificity in this diagnostic context (58.8% vs 70.6%, P=0.473). Conclusion: These results demonstrate that BSGI is a useful auxiliary approach to evaluating pCR to NAC treatment.
Keywords
breast-specific gamma imaging (BSGI); neoadjuvant chemotherapy (NAC); breast cancer; Magnetic resonance imaging (MRI); residual tumor size
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
